ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and ...

The global breast cancer therapeutics market is expected to grow from US$ 31.07 billion in 2022 to US$ 63.9 billion by 2030, ...

Factors influencing this expansion include: The growing prevalence of breast cancer plays ... Kadcyla is a targeted treatment that integrates the HER2-targeting antibody trastuzumab with the ...

Triple negative breast cancer accounts for 15% of cases but causes a disproportionate number of deaths. Learn about symptoms ...

Tucatinib inhibits the tyrosine kinase enzyme of the HER-2 gene. Mutations of tyrosine kinase in the HER-2 gene lead to ...

Rise in prevalence of cancer and the necessary attention in early diagnosis and treatment to boost market demand, States Fact.MRRockville, MD, ...

A multinational healthcare company, Roche and a provider of digital integrated healthcare services, Oncopadi Technologies ...

Aliya Omer, VP, US franchise head, breast cancer, AstraZeneca, discusses Lynparza’s role in reducing the risk of invasive disease recurrence or death in HR-positive breast cancer patients.

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful ...